A Phase 1/2 interventional study of BI-1206 single agent dose escalation phase and Combination of BI-1206 with rituximab escalation phase in B-cell Lymphoma, Chronic Lymphocytic Leukaemia and Waldenström Macroglobulinemia, sponsored by Cancer Research UK. Completed at 5 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-08.
Sponsored by Cancer Research UK · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Lymphoma, B-Cell with a site in United Kingdom — 14 open to participants now, 29 under way, 10 of them phase 3. Lymphoma, B-Cell · United Kingdom.
Among the 64 studies in Lymphoma, B-Cell with a site in United Kingdom, this one is the 56th largest by enrollment of the 59 interventional ones that give a count, is one of 4 that started in 2016, is one of 17 in phase 1/2, and was the 25th registered.
889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.
Browse Lymphoma, B-Cell studies →14 of the 64 studies in Lymphoma, B-Cell with a site in United Kingdom are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United Kingdom, United States, Australia and 9 more countries
Ages 18+
AstraZeneca · Sites in United Kingdom, Australia, Belgium and 9 more countries
Ages 65–130
AstraZeneca · Sites in United Kingdom, United States, Australia and 5 more countries
Ages 18+
BeOne Medicines · Sites in United Kingdom, United States, Argentina and 14 more countries
Ages 18+
AstraZeneca · Sites in United Kingdom, United States, Australia and 10 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 209 Lymphoma, B-Cell studies recruiting now, 128 (61%) set no upper age limit and 61 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 29 · Phase 3 17 · Phase 4 1
First in 1996; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 34 across 775 interventional studies indexed under Lymphoma, B-Cell.
Median enrollment 166 across the 59 interventional studies, 247 across the 5 observational. Of the 33 that completed or were terminated, 17 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 64 have an industry lead sponsor. The 10 most frequent:
Cancer Research UK is the lead sponsor of 83 studies on the registry; 12 are open to participants now.
Cancer Research UK has 3 studies filed under Lymphoma, B-Cell — fewer than ten, so there is no comparison to draw.
10 of the studies in Lymphoma, B-Cell with a site in United Kingdom that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05254743Phase 3Loxo Oncology, Inc.A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | 2027-10 |
| NCT06047080Phase 3Hoffmann-La RocheAn Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | 2027-10-01 |
| NCT04662255Phase 3Loxo Oncology, Inc.Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | 2027-11 |
| NCT05463263Step Pharma, SASA Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas | 2026-12 |
| NCT05784441Janssen Research & Development, LLCA Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) | 2027-01-06 |
Add all 10 to your calendar (.ics) → With an account.
Among the 64 studies in Lymphoma, B-Cell with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to identify the tolerable dose of BI-1206 (both alone and in combination) for patients with B-cell lymphoma and leukaemia and further evaluate BI-1206 alone and in combination with an anti-CD20 antibody.
The molecule CD32b is thought to be present on many B-cells including the malignant B-cells in some types of lymphoma and leukaemia. The study drug, BI-1206, is an anti-CD32b monoclonal antibody which attaches to CD32b on the surface of B-cells and is thought to act by recruiting host immune cells toward the tumour leading to cancer cell death as well as enhancing the anti-cancer effect of other anti-CD20 antibodies such as rituximab by stopping them being absorbed by cells.
The study is a first in man clinical trial of the drug called BI-1206 on its own and then also in combination with an anti-CD20 antibody (such as rituximab) which is commonly used to treat lymphoma and some types of leukaemia.
The four main aims of this trial are to find out:
Approximately 81 patients with relapsed or refractory CD32b positive B-cell lymphoma or leukaemia were planned for the trial. Approximately 34 patients to establish the maximum tolerated doses (MTDs) in Part A and a further 40 to 50 patients recruited to two expansion cohorts; one of BI-1206 alone and one of BI-1206 plus rituximab (Part B). The final number depending on the number of dose escalations required to reach the MTD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Haematological and biochemical indices within the ranges shown below. These measurements must be performed within one week before their first dose of mAb (BI-1206 and/or rituximab) as part of this study.
Laboratory Test Value required
(Hb) ≥9.0 g/dL (red cell support is permissible)
(ANC) ≥1.0 x 10\^9/L (or >0.5 x 10\^9/L if due to lymphoma), granulocyte - colony stimulating factor (G-CSF) support is not permissible at screening
count ≥50 x 10\^9/L (or ≥30 x 10\^9/L if due to malignant involvement of bone marrow)
Either:
Serum ≤1.5 x (ULN) unless raised due to Gilbert's syndrome in which case up to 3 x ULN is permissible.
Or:
Alanine amino-transferase () and /or aspartate amino-transferase (AST) ≤ 2.5 x ULN unless raised due to malignant hepatic involvement in which case up to 5 x ULN is permissible
Either:
Calculated (Cockcroft Gault) ≥30 mL/min (uncorrected value)
Or:
Isotope clearance measurement ≥30 mL/min (corrected)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).
Biological: BI-1206 single agent dose escalation phase
Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).
Biological: Combination of BI-1206 with rituximab escalation phase
Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 chronic lymphocytic leukaemia (CLL) patients and six mantle cell lymphoma (MCL) patients.
Biological: BI-1206 single agent expansion phase
Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.
Biological: Combination of BI-1206 with rituximab expansion phase
BI-1206 single agent dose escalation phase to determine the MTD or maximum administered dose (MAD) and recommended Phase II dose (RP2D) for evaluation of BI-1206.
An investigation of combination treatment of BI-1206 with rituximab.
BI-1206 single agent expansion phase at the RP2D.
BI-1206 in combination with rituximab at the RP2D.
Documenting Adverse Events (AEs), Serious Adverse Events (SAEs), Dose Limiting Toxicities (DLTs) (Graded According to NCI-CTCAE Version 4.02) and Laboratory Parameters and Determining Their Causality in Relation to BI-1206.
To recommend a dose for future trials with BI-1206 by finding the highest safe dose which can be given to patients.
Time frame: Safety data were collected from the date of written informed consent and continued for 125 days after the final administration of BI-1206 or rituximab.
Documenting AEs, SAEs (Graded According to NCI-CTCAE Version 4.02) and Laboratory Parameters and Determining Their Causality in Relation to BI-1206 and, Where Appropriate, Anti-CD20 Antibody.
Establishing the MTD or maximum administered dose MAD of BI-1206 and an anti-CD20 antibody given once weekly for four weeks, via intravenous infusion in patients with relapsed or refractory B-cell malignancies.
Time frame: Safety data were collected from the date of written informed consent and continued for 125 days after the final administration of BI-1206 or rituximab.
Measurement of PK Parameter Maximum Observed Serum Concentration (Cmax) for BI-1206
Maximum observed serum concentration after intravenous BI-1206 administration
Time frame: Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)
Measurement of PK Parameter Area Under the Serum Concentration-time Curve From Time 0 to the Last Time Point (AUClast) for BI-1206
Area under the serum concentration-time curve from time 0 to the last time point after intravenous BI-1206 administration.
Time frame: Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)
Measurement of PK Parameter Half-life (T1/2) for BI-1206
BI-1206 half-life after intravenous administration
Time frame: Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)
Measurement of PK Parameter Total Body Clearance (CL) for BI-1206
Total body clearance after intravenous BI-1206 administration
Time frame: Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)
Measurement of PK Parameter Volume of Distribution (Vss) for BI-1206
Volume of distribution after administration of BI-1206
Time frame: Doses 1 and 4 (pre-infusion, end of infusion, +4, +24, +48 and +72 hours)
Measurement of Anti-drug Antibody (ADA) Response to BI-1206 During the BI-1206 Treatment Period Using ELISA
Patients with true ADA response
Time frame: Pre dose at weeks 1, 5 and 8, maintenance phase and off-study visit.
Measurement of Peripheral Blood B-lymphocyte Depletion During the BI-1206 Treatment Period Using Flow Cytometry.
Number of patients with B-lymphocyte depletion during BI-1206 treatment period.
Time frame: During induction phase (up to 8 weeks).
Assessment of Best Disease Response According to Criteria for Malignant Lymphoma (Cheson, 2014) Waldenström Macroglobulinaemia Assessment Criteria (Owen 2013, Kimby 2006) or NCI Chronic Lymphocytic Leukaemia (CLL) Criteria (Hallek, 2008).
To look for signs of anti-tumour activity of BI-1206 alone and in combination in patients with relapsed or refractory B-cell malignancies
Time frame: Response evaluated 4 weeks after last dose in induction phase, every 16 weeks during maintenance phase and at off-study.
Measure Progression Free Survival at 1 Year After the First BI-1206 Administration on the Study for All Patients
To measure the time to disease progression and twelve month survival
Time frame: From first BI-1206 administration up to 12 months
Measure Overall Survival at 1 Year After the First BI-1206 Administration on the Study for All Patients
To measure the time to disease progression and twelve month survival
Time frame: From first BI-1206 administration up to 12 months. Participants whose last reported status was not death were censored.
Trial participants were enrolled at four trial sites between 27 October 2016 and 09 December 2019.
| Milestone | Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase | Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase | Part B: Arm1: BI-1206 Single Agent Expansion Phase | Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase |
|---|---|---|---|---|
| Started | 13 | 1 | 0 | 0 |
| Completed | 13 | 1 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
To recommend a dose for future trials with BI-1206 by finding the highest safe dose which can be given to patients.
| Number of events | Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase | Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase | Part B: Arm1: BI-1206 Single Agent Expansion Phase | Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase |
|---|---|---|---|---|
| All AEs | 282 | 13 | — | — |
| Related AEs | 214 | 12 | — | — |
| DLT - ALT | 1 | 0 | — | — |
| DLT - AST | 1 | 0 | — | — |
| DLT - infusion related reaction | 0 | 1 | — | — |
Establishing the MTD or maximum administered dose MAD of BI-1206 and an anti-CD20 antibody given once weekly for four weeks, via intravenous infusion in patients with relapsed or refractory B-cell malignancies.
| BI-1206 MAD (mg) | Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase | Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase | Part B: Arm1: BI-1206 Single Agent Expansion Phase | Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase |
|---|---|---|---|---|
| Documenting AEs, SAEs (Graded According to NCI-CTCAE Version 4.02) and Laboratory Parameters and Determining Their Causality in Relation to BI-1206 and, Where Appropriate, Anti-CD20 Antibody. | 100 | NA | — | — |
Maximum observed serum concentration after intravenous BI-1206 administration
| ng/mL | Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase | Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase | Part B: Arm1: BI-1206 Single Agent Expansion Phase | Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase |
|---|---|---|---|---|
| 0.4 - 50 mg BI-1206 (Cohort 1, intra patient dose escalation) | 6075 (31.2 to 13100) | — | — | — |
| 100 mg BI-1206 (Cohort 2) Dose 1 | 15600 (6990 to 19300) | — | — | — |
| 100 mg BI-1206 (Cohort 2) Dose 4 | 12700 (8850 to 22500) | — | — | — |
Area under the serum concentration-time curve from time 0 to the last time point after intravenous BI-1206 administration.
| h*ng/mL | Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase | Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase | Part B: Arm1: BI-1206 Single Agent Expansion Phase | Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase |
|---|---|---|---|---|
| 0.4 - 50 mg BI-1206 (Cohort 1, intra patient dose escalation) | 76100 (9.1 to 384000) | — | — | — |
| 100 mg BI-1206 (Cohort 2) Dose 1 | 462000 (129000 to 594000) | — | — | — |
| 100 mg BI-1206 (Cohort 2) Dose 4 | 193000 (168000 to 733000) | — | — | — |
BI-1206 half-life after intravenous administration
| h | Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase | Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase | Part B: Arm1: BI-1206 Single Agent Expansion Phase | Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase |
|---|---|---|---|---|
| 0.4 - 2 mg BI-1206 (Cohort 1, starting dose and first intra patient escalation dose) | NA (NA to NA) | — | — | — |
| 10 - 50 mg BI-1206 (Cohort 1, intra patient dose escalation) | 17.3 (9.3 to 18.9) | — | — | — |
| 100 mg BI-1206 (Cohort 2) Dose 1 | 16 (11.5 to 21.6) | — | — | — |
| 100 mg BI-1206 (Cohort 2) Dose 4 | 12.1 (10.8 to 46.6) | — | — | — |
Total body clearance after intravenous BI-1206 administration
| mL/h/kg | Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase | Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase | Part B: Arm1: BI-1206 Single Agent Expansion Phase | Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase |
|---|---|---|---|---|
| 0.4 - 2 mg BI-1206 (Cohort 1, starting dose and first intra patient escalation dose) | NA (NA to NA) | — | — | — |
| 10 - 50 mg BI-1206 (Cohort 1 intra patient dose escalation) | 6.34 (2.45 to 10.8) | — | — | — |
| 100 mg BI-1206 (Cohort 2) Dose 1 | 3.32 (1.82 to 9.63) | — | — | — |
| 100 mg BI-1206 (Cohort 2) Dose 4 | 7.44 (6.61 to 8.64) | — | — | — |
Volume of distribution after administration of BI-1206
| mL/kg | Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase | Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase | Part B: Arm1: BI-1206 Single Agent Expansion Phase | Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase |
|---|---|---|---|---|
| 0.4 - 2 mg BI-1206 (Cohort 1, starting dose and first intra patient escalation dose) | NA (NA to NA) | — | — | — |
| 10 - 50 mg BI-1206 (Cohort 1, intra patient dose escalation) | 84.2 (60.6 to 208) | — | — | — |
| 100 mg BI-1206 (Cohort 2) Dose 1 | 81.0 (50.5 to 182) | — | — | — |
| 100 mg BI-1206 (Cohort 2) Dose 4 | 126 (124 to 143) | — | — | — |
Patients with true ADA response
| Participants | Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase | Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase | Part B: Arm1: BI-1206 Single Agent Expansion Phase | Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase |
|---|---|---|---|---|
| Measurement of Anti-drug Antibody (ADA) Response to BI-1206 During the BI-1206 Treatment Period Using ELISA | 0 | 0 | — | — |
Number of patients with B-lymphocyte depletion during BI-1206 treatment period.
| Participants | Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase | Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase | Part B: Arm1: BI-1206 Single Agent Expansion Phase | Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase |
|---|---|---|---|---|
| Measurement of Peripheral Blood B-lymphocyte Depletion During the BI-1206 Treatment Period Using Flow Cytometry. | 0 | 0 | — | — |
To look for signs of anti-tumour activity of BI-1206 alone and in combination in patients with relapsed or refractory B-cell malignancies
| Participants | Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase | Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase | Part B: Arm1: BI-1206 Single Agent Expansion Phase | Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase |
|---|---|---|---|---|
| Stable disease | 3 | 0 | — | — |
| Progressive disease | 7 | 0 | — | — |
| Not evaluable | 3 | 1 | — | — |
To measure the time to disease progression and twelve month survival
| Participants | Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase | Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase | Part B: Arm1: BI-1206 Single Agent Expansion Phase | Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase |
|---|---|---|---|---|
| Progression free & alive | 2 | 0 | — | — |
| Progressed, died or unknown | 11 | 1 | — | — |
To measure the time to disease progression and twelve month survival
| Days | Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase | Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase | Part B: Arm1: BI-1206 Single Agent Expansion Phase | Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase |
|---|---|---|---|---|
| Measure Overall Survival at 1 Year After the First BI-1206 Administration on the Study for All Patients | 152.2 (38 to 360) | — | — | — |
Collected over Safety data were collected from the date of written informed consent and continued for 125 days after the final administration of BI 1206 or rituximab. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase | 1/13 (7.7%) | 10/13 (76.9%) | 13/13 (100%) |
| Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Part B: Arm1: BI-1206 Single Agent Expansion Phase | — | — | — |
| Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase | — | — | — |
| Event | Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase | Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase | Part B: Arm1: BI-1206 Single Agent Expansion Phase | Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase |
|---|---|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 5/13 | 1/1 | — | — |
| PneumoniaInfections and infestations | 2/13 | 0/1 | — | — |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/13 | 0/1 | — | — |
| Atrial fibrillationCardiac disorders | 1/13 | 0/1 | — | — |
| Abdominal painGastrointestinal disorders | 1/13 | 0/1 | — | — |
| DiarrhoeaGastrointestinal disorders | 1/13 | 0/1 | — | — |
| Non-cardiac chest painGeneral disorders | 1/13 | 0/1 | — | — |
| Abdominal abscessInfections and infestations | 1/13 | 0/1 | — | — |
| Lower respiratory tract infectionInfections and infestations | 1/13 | 0/1 | — | — |
| Metapneumovirus infectionInfections and infestations | 1/13 | 0/1 | — | — |
| Event | Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase | Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase | Part B: Arm1: BI-1206 Single Agent Expansion Phase | Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase |
|---|---|---|---|---|
| TachycardiaCardiac disorders | 4/13 | 1/1 | — | — |
| Infusion related reactionInjury, poisoning and procedural complications | 9/13 | 1/1 | — | — |
| Alanine aminotransferase increasedInvestigations | 2/13 | 1/1 | — | — |
| Aspartate aminotransferase increasedInvestigations | 1/13 | 1/1 | — | — |
| Platelet count decreasedInvestigations | 2/13 | 1/1 | — | — |
| HyperglycaemiaMetabolism and nutrition disorders | 1/13 | 1/1 | — | — |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/13 | 1/1 | — | — |
| UrticariaSkin and subcutaneous tissue disorders | 8/13 | 1/1 | — | — |
| HypotensionVascular disorders | 6/13 | 1/1 | — | — |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 0/13 | 1/1 | — | — |
Trial terminated before opening Part B.
| Age, Categorical(Participants) | Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase | Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase | Part B: Arm1: BI-1206 Single Agent Expansion Phase | Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | — | — | 0 |
| Between 18 and 65 years | 5 | 1 | — | — | 6 |
| >=65 years | 8 | 0 | — | — | 8 |
| Sex: Female, Male(Participants) | Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase | Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase | Part B: Arm1: BI-1206 Single Agent Expansion Phase | Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase | Total |
|---|---|---|---|---|---|
| Female | 5 | 1 | — | — | 6 |
| Male | 8 | 0 | — | — | 8 |
| Race and Ethnicity Not Collected(Participants) | Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase | Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase | Part B: Arm1: BI-1206 Single Agent Expansion Phase | Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase | Total |
|---|---|---|---|---|---|
| Count of participants | — | — | — | — | 0 |
| Region of Enrollment(participants) | Part A: Arm 1: BI-1206 Single Agent Dose Escalation Phase | Part A: Arm 2: Combination of BI-1206 With Rituximab Escalation Phase | Part B: Arm1: BI-1206 Single Agent Expansion Phase | Part B: Arm 2: Combination of BI-1206 With Rituximab Expansion Phase | Total |
|---|---|---|---|---|---|
| United Kingdom | 13 | 1 | — | — | 14 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2016 to primary completion in Mar 2020, 40 months.
Results were first posted in Jul 2021, 1 year 3 months after primary completion.
Of 52 non-industry phase 1/2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 82. This study's 40 months is below that.
Counting every sponsor, half of 94 studies reached it within 71 months; a quarter within 55 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BI-1206
Cancer Research UK